Acute and late changes in intraarticular cytokine levels following anterior cruciate ligament injury

Journal of Orthopaedic Research

Volumn 31, Issue 2, 2013, Pages 315-321

  Bigoni, Marco ^a   Sacerdote, Paola ^b   Turati, Marco ^a   Franchi, Silvia ^b   Gandolla, Marta ^c   Gaddi, Diego ^a   Moretti, Sarah ^b   Munegato, Daniele ^a   Augusti, Carlo A ^a   Bresciani, Elena ^d   Omeljaniuk, Robert J ^e   Locatelli, Vittorio ^d   Torsello, Antonio ^d  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c POLITECNICO DI MILANO   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e LAKEHEAD UNIVERSITY   (Canada)

Author keywords

ACL tear; cytokines; knee; osteoarthritis; synovial

Indexed keywords

CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTORALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ANTERIOR CRUCIATE LIGAMENT INJURY; ANTERIOR CRUCIATE LIGAMENT RUPTURE; ARTICLE; CARTILAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; HUMAN; INJURY SCALE; JOINT EFFUSION; KNEE OSTEOARTHRITIS; MALE; PRIORITY JOURNAL; SYNOVIAL FLUID;

ADOLESCENT; ADULT; ANTERIOR CRUCIATE LIGAMENT; CARTILAGE, ARTICULAR; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; KNEE INJURIES; MALE; OSTEOARTHRITIS; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871616795     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22208     Document Type: Article

References (22)

1. Lohmander LS, Englund PM, Dahl LL, et al. 2007. The long-term consequence of anterior cruciate ligament and meniscus injuries: osteoarthritis. Am J Sports Med 35: 1756-1769.
2. Oiestad BE, Engebretsen L, Storheim K, et al. 2009. Knee osteoarthritis after anterior cruciate ligament injury: a systematic review. Am J Sports Med 37: 1434-1443.
3. Noyes FR, Mooar PA, Matthews DS, et al. 1983. The symptomatic anterior cruciate-deficient knee. Part I: The long-term functional disability in athletically active individuals. J Bone Joint Surg Am 65: 154-162.
4. Ferretti A, Conteduca F, De Carli A, et al. 1991. Osteoarthritis of the knee after ACL reconstruction. Int Orthop 15: 367-371.
5. Irie K, Uchiyama E, Iwaso H,. 2003. Intraarticular inflammatory cytokines in acute anterior cruciate ligament injured knee. Knee 10: 93-96.
6. Campbell IK, Piccoli DS, Roberts MJ, et al. 1990. Effects of tumor necrosis factor alpha and beta on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 33: 542-552.
7. Marks PH, Donaldson ML,. 2005. Inflammatory cytokine profiles associated with chondral damage in the anterior cruciate ligament-deficient knee. Arthroscopy 21: 1342-1347.
8. Bianchi M, Broggini M, Balzarini P, et al. 2007. Effects of nimesulide on pain and on synovial fluid concentrations of substance p, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib. Int J Clin Pract 61: 1270-1277.
9. Cameron M, Buchgraber A, Passler H, et al. 1997. The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations. Am J Sports Med 25: 751-754.
10. Higuchi H, Shirakura K, Kimura M, et al. 2006. Changes in biochemical parameters after anterior cruciate ligament injury. Int Orthop 30: 43-47.
11. Daniel DM, Stone ML, Dobson BE, et al. 1994. Fate of the ACL-injured patient. A prospective outcome study. Am J Sports Med 22: 632-644.
12. Louboutin H, Debarge R, Richou J, et al. 2009. Osteoarthritis in patients with anterior cruciate ligament rupture: a review of risk factors. Knee 16: 239-244.
13. Bettinger DA, Pellicane JV, Tarry WC, et al. 1994. The role of inflammatory cytokines in wound healing: accelerated healing in endotoxin-resistant mice. J Trauma 36: 810-813; discussion 813-814.
14. Mooney DP, O'Reilly M, Gamelli RL,. 1990. Tumor necrosis factor and wound healing. Ann Surg 211: 124-129.
15. Guerne PA, Carson DA, Lotz M,. 1990. IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. J Immunol 144: 499-505.
16. Nakahara H, Song J, Sugimoto M, et al. 2003. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521-1529.
17. Nishimoto N, Yoshizaki K, Miyasaka N, et al. 2004. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761-1769.
18. Suzuki M, Hashizume M, Yoshida H, et al. 2010. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6r antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 30: 309-315.
19. Fernandes JC, Martel-Pelletier J, Pelletier JP,. 2002. The role of cytokines in osteoarthritis pathophysiology. Biorheology 39: 237-246.
20. D'Andrea A, Aste-Amezaga M, Valiante NM, et al. 1993. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 178: 1041-1048.
21. Schulze-Tanzil G, Zreiqat H, Sabat R, et al. 2009. Interleukin-10 and articular cartilage: experimental therapeutical approaches in cartilage disorders. Curr Gene Ther 9: 306-315.
22. Ogata A, Hirano T, Hishitani Y, et al. 2012. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord 5: 27-42.